Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.
Population pharmacokinetic analysis demonstrated that renal function, as assessed by creatinine clearance (CL(CR)), was the patient characteristic that had a clinically relevant impact on ceftobiprole pharmacodynamics. Dosing adjustments based on CL(CR) for subjects with renal impairment should provide ceftobiprole exposure similar to that in patients with normal renal function.
Kimko
Holly
H
Johnson & Johnson Pharmaceutical Research & Development, LLC, South Raritan, NJ 08869, USA. HKimko@its.jnj.com
Murthy
Bindu
B
Xu
Xu
X
Nandy
Partha
P
Strauss
Richard
R
Noel
Gary J
GJ
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016022:Case-Control Studies; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017326:Clinical Trials, Phase III as Topic; D003198:Computer Simulation; D003404:Creatinine / Q000493:pharmacokinetics; D006801:Humans; D007262:Infusions, Intravenous; D007677:Kidney Function Tests; D008297:Male; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D011153:Population / Q000235:genetics; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D012984:Software
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole; D003404:Creatinine